ErbB公司
曲妥珠单抗
ERBB3型
ERBB4公司
受体酪氨酸激酶
癌症研究
受体
表皮生长因子受体
化学
酪氨酸激酶
拉帕蒂尼
生物
表皮生长因子
抗体
癌症
单克隆抗体
乳腺癌
细胞生物学
细胞外
免疫学
生物化学
遗传学
作者
Hyun‐Soo Cho,Karen Mason,Kasra X. Ramyar,Ann Marie Stanley,Sandra B. Gabelli,Dan W. Denney,Daniel J. Leahy
出处
期刊:Nature
[Springer Nature]
日期:2003-02-01
卷期号:421 (6924): 756-760
被引量:1491
摘要
HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4). ErbB receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues, and their inappropriate activation is associated with the development and severity of many cancers. Overexpression of HER2 is found in 20-30% of human breast cancers, and correlates with more aggressive tumours and a poorer prognosis. Anticancer therapies targeting ErbB receptors have shown promise, and a monoclonal antibody against HER2, Herceptin (also known as trastuzumab), is currently in use as a treatment for breast cancer. Here we report crystal structures of the entire extracellular regions of rat HER2 at 2.4 A and human HER2 complexed with the Herceptin antigen-binding fragment (Fab) at 2.5 A. These structures reveal a fixed conformation for HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB receptors in the absence of direct ligand binding. Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI